

Special Dispatch: FDA Rejects Lykos’ MDMA Assisted Therapy Application
31 snips Aug 13, 2024
Dr. Carlene MacMillan, a Harvard-trained psychiatrist and Chief Medical Officer at Osmind, shares her insights on the recent FDA rejection of Lykos Therapeutics' MDMA-assisted therapy. She discusses the complexities of psychiatric trials, research misconduct allegations, and the role of reliable data in therapy approval. The conversation also highlights challenges in integrating innovative treatments into the healthcare system and the push for value-based care. Dr. MacMillan emphasizes the importance of collaboration and the future of psychedelic therapies in mental health.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Intro
00:00 • 2min
Navigating the FDA's MDMA Therapy Rejection
01:47 • 24min
Navigating Healthcare Challenges for MDMA Therapy
26:09 • 11min
Advancing Psychiatry Through Innovation and Collaboration
37:08 • 3min
Exploring Frontier Treatments for PTSD
40:37 • 2min
Advancements in Interventional Psychiatry and Future Directions
42:38 • 2min